Optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma is suspected: a single-center study.
Adult
Aged
Disease-Free Survival
Female
Humans
Liposarcoma
/ mortality
Male
Middle Aged
Neoplasm Recurrence, Local
/ diagnostic imaging
Postoperative Care
Prognosis
Proportional Hazards Models
Retroperitoneal Neoplasms
/ mortality
Salvage Therapy
/ methods
Survival Rate
Time Factors
Tomography, X-Ray Computed
Recurrent retroperitoneal liposarcoma
Retroperitoneal liposarcoma
Retroperitoneal soft tissue sarcoma
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
05
07
2018
accepted:
18
12
2018
pubmed:
4
1
2019
medline:
11
7
2019
entrez:
4
1
2019
Statut:
ppublish
Résumé
This study was designed to identify the optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma (LPS) is suspected. Patients who underwent salvage operation at Samsung Medical Center for recurrent retroperitoneal LPS from January 2000 to December 2015 were reviewed. The time interval between recurrence and operation for recurrence was divided by 1, 2 or 3 months. A Cox proportional-hazards model was used to analyze factors related to disease-free survival along with recurrence-to-operation interval divided by 1, 2 or 3 months. The 1-, 3-, and 5-year disease-free survival rates were 43.2%, 15.6% and 13.4%, respectively. FNCLCC grade (p = 0.023) and recurrence-to-operation interval divided by 3 months (p = 0.003) were significant factors associated with recurrence. FNCLCC grade 2 (HR 1.940, CI 0.935-4.026, p = 0.238) and grade 3 (HR 4.049, CI 1.767-9.281, p = 0.007) showed increased risk compared to grade 1. Patients who underwent salvage operation more than 3 months after recurrence showed significantly increased risk of recurrence compared to patients within 3 months (HR 2.724, CI 1.391-5.337, p = 0.003). Based on our analysis of recurrence-free survival, salvage operation can be delayed for less than 3 months when recurrence is suspected. A short-term follow-up imaging study should be performed within this period.
Sections du résumé
BACKGROUND
BACKGROUND
This study was designed to identify the optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma (LPS) is suspected.
METHODS
METHODS
Patients who underwent salvage operation at Samsung Medical Center for recurrent retroperitoneal LPS from January 2000 to December 2015 were reviewed. The time interval between recurrence and operation for recurrence was divided by 1, 2 or 3 months. A Cox proportional-hazards model was used to analyze factors related to disease-free survival along with recurrence-to-operation interval divided by 1, 2 or 3 months.
RESULTS
RESULTS
The 1-, 3-, and 5-year disease-free survival rates were 43.2%, 15.6% and 13.4%, respectively. FNCLCC grade (p = 0.023) and recurrence-to-operation interval divided by 3 months (p = 0.003) were significant factors associated with recurrence. FNCLCC grade 2 (HR 1.940, CI 0.935-4.026, p = 0.238) and grade 3 (HR 4.049, CI 1.767-9.281, p = 0.007) showed increased risk compared to grade 1. Patients who underwent salvage operation more than 3 months after recurrence showed significantly increased risk of recurrence compared to patients within 3 months (HR 2.724, CI 1.391-5.337, p = 0.003).
CONCLUSIONS
CONCLUSIONS
Based on our analysis of recurrence-free survival, salvage operation can be delayed for less than 3 months when recurrence is suspected. A short-term follow-up imaging study should be performed within this period.
Identifiants
pubmed: 30604162
doi: 10.1007/s10147-018-01383-w
pii: 10.1007/s10147-018-01383-w
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-589Références
Br J Surg. 2000 Mar;87(3):259-60
pubmed: 10718790
Chir Ital. 2001 Jan-Feb;53(2):149-57
pubmed: 11396061
Cancer. 2001 Jul 15;92(2):359-68
pubmed: 11466691
Cancer. 2004 Jun 1;100(11):2448-55
pubmed: 15160351
J Surg Oncol. 2005 Jul 1;91(1):1-9
pubmed: 15999353
J Urol. 2007 Mar;177(3):1145
pubmed: 17296434
Br J Surg. 2007 Sep;94(9):1057-8
pubmed: 17701955
World J Surg Oncol. 2008 Oct 31;6:115
pubmed: 18976464
AJR Am J Roentgenol. 2008 Dec;191(6):1841-6
pubmed: 19020257
J Clin Oncol. 2009 Jan 1;27(1):31-7
pubmed: 19047280
J Clin Oncol. 2009 Jan 1;27(1):24-30
pubmed: 19047283
Eur J Surg Oncol. 2009 Sep;35(9):986-93
pubmed: 19138832
Oncologist. 2009 Oct;14(10):1021-38
pubmed: 19789392
Br J Surg. 2010 May;97(5):698-706
pubmed: 20306527
J Clin Oncol. 2013 May 1;31(13):1649-55
pubmed: 23530096
Ann Oncol. 2014 Mar;25(3):730-4
pubmed: 24496921
Curr Probl Surg. 1970 Mar;:1-60
pubmed: 4190913
Ann Surg. 1995 Feb;221(2):185-95
pubmed: 7857146
J Surg Oncol. 1994 Aug;56(4):213-6
pubmed: 8057644
Can Assoc Radiol J. 1996 Oct;47(5):335-41
pubmed: 8857967